WASHINGTON, DC—Early-stage cardiogenic shock leads to poor outcomes but is underrecognized, with only one in four affected patients having any indication in their electronic medical record (EMR) that ...
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback